"Serum Institute"

Latest news and video coverage curated from trusted media outlets

You Might Like

Karan on selling 50 per cent of Dharma to Poonawalla In 2024, Karan Johar made headlines when he sold a 50 percent stake of his production company, Dharma Productions, to Serum Institute of India CEO Adar Poonawalla for a staggering Rs 1,000 crore. In a.. IndiaTimes - Published on May 7, 2025
SII CEO Adar Poonawalla buys Rs 1.04 crore matte black Land Rover Defender 110 X for... Indian billionaires are known for their luxurious lifestyles, often accompanied by an impressive fleet of vehicles and security cars. Adar Poonawalla, CEO of Serum Institute of India, is no exception. DNA - Published on March 5, 2025
After Anand Mahindra, Adar Poonawalla responds to L&T chief's 90-hour work week remark: 'My wife loves staring at me' Adar Poonawalla, CEO of the Serum Institute of India, backed Mahindra Group Chairman Anand Mahindra's call for prioritising quality over quantity in work hours DNA - Published on January 12, 2025
Karan posts cryptic message after Jaaved mocks deal Karan Johar recently made waves in the industry by selling a 50 per cent stake in Dharma Productions to Adar Poonawalla, CEO of Serum Institute. Though the reason behind Johar’s search for an.. IndiaTimes - Published on October 27, 2024
Meet Pune's richest man who owns Rs 750 crore home, has net worth of over Rs 204300 crore, he is... This is one of India's richest man who built the Serum Institute into the world's largest vaccine producer amassing a fortune of Rs 2,89,900 crore. DNA - Published on October 25, 2024
Supreme Court bins pleas for probe into Covid jab side-effects The Supreme Court dismissed a PIL seeking an investigation into alleged side effects of the Covishield vaccine, developed by AstraZeneca and Oxford and produced by Serum Institute of India. The.. IndiaTimes - Published on October 14, 2024
Serum Institute of India (SII) working on vaccine for Mpox outbreak: CEO Adar Poonawalla Following the state government's guidelines on Mpox response, Serum Institute of India (SII) CEO Adar Poonawalla announced ongoing efforts to develop a vaccine, expecting positive results within a.. IndiaTimes - Published on August 21, 2024
Meet Indian, who owns over Rs 1400 crore mansion in London, much costlier than Mukesh Ambani, Lakshmi Mittal's UK homes Serum Life Sciences, a UK-based subsidiary of the Poonawalla family's Serum Institute of India, will acquire the property, the reported quoted people familiar with the transaction as saying. DNA - Published on August 3, 2024
Serum to buy 20% in med tech firm Serum Institute of India (SII) invested in IntegriMedical, a med tech firm, for needle-free injection system tech. The partnership aims to provide 'health for all' and 'transform healthcare globally'.. IndiaTimes - Published on May 17, 2024
WHO approves Japan-made dengue vaccine WHO approves TAK-003 (Qdenga) as 2nd dengue vaccine for children aged 6-16 in high-burden areas. Takeda in talks to launch in India. Panacea Biotec & Serum Institute collaborate on indigenous vaccine.. IndiaTimes - Published on May 16, 2024
1 in 3 Covaxin recipients hit by adverse events: Study Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual.. IndiaTimes - Published on May 16, 2024
TOI Health News Morning Briefing Here is the TOI health news morning briefing. Legal action against Serum Institute over Covid deaths. AstraZeneca admits side effects. India reports FLiRT COVID variants. 91 cases of the new Covid-19.. IndiaTimes - Published on May 13, 2024
Kin claim deaths due to Covishield, to sue Serum Institute of India Parents sue Covishield maker over side-effects deaths, halted production due to reduced demand post high vaccination rates. Legal action in Supreme Court confirmed vaccine as the cause of deaths. IndiaTimes - Published on May 12, 2024	Covishield side effects disclosed in packaging: SII Serum Institute of India stopped Covishield production due to reduced demand post high vaccination rates. They disclosed rare side effects like Thrombosis with thrombocytopenia syndrome since 2021,.. IndiaTimes - Published on May 9, 2024
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recall UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped.. IndiaTimes - Published on May 8, 2024	AstraZeneca withdraws COVID vaccine worldwide AstraZeneca withdraws COVID vaccine worldwide due to TTS. Facing 100 million pound lawsuit. TTS involves blood clots, low platelets. Symptoms: severe headache, abdominal pain. Treatment: anticoagulant.. IndiaTimes - Published on May 8, 2024
Sharad Pawar seeks Bharat Ratna for Dr Poonawalla Former Union minister Sharad Pawar on Wednesday heaped praises on Dr Cyrus Poonawalla, founder of Serum Institute of India (SII), for his work in the field of vaccine production, and demanded that he.. Mid-Day - Published on February 14, 2024	Meet woman, executive director of Rs 192000 crore company, known for glamorous and stylish life Natasha Poonawalla, who is enthusiastic about fashion and design. She is currently serving as the executive director of the Serum Institute of India (SII), one of the biggest producers of vaccines.. DNA - Published on February 2, 2024
Meet Pune's richest man with net worth of Rs 166500 crore, is founder of world's largest pharmaceutical company, he is.. He played a crucial role as the leader of the Serum Institute of India in the large-scale production of the Covishield vaccine amid the Covid-19 pandemic. DNA - Published on January 12, 2024	Adar Poonawala's mansion worth Rs 1446 crore For those not aware of the name, Adar Poonawala is the CEO of Serum Institute of India, a company that achieved great success in vaccine making and distribution during the COVID pandemic. IndiaTimes - Published on December 14, 2023
Imposition of tax on subsidies does not constitute 'taking away' of a benefit : Bombay HC; dismisses challenge by Serum Institute The Bombay High Court dismissed a petition filed by Serum Institute of India Pvt Ltd challenging a 2016 amendment to the Income Tax Act, 2015. The amendment included subsidies, grants, and incentives.. IndiaTimes - Published on December 4, 2023	Meet man who owns exotic Rolls-Royce collection, cars worth over Rs 100 crore, not Mukesh Ambani, Ratan Tata, Adani Yohan Poonawalla is son of Zavaray Poonawalla who co-founded biopharmaceuticals firm Serum Institute of India along with his brother Cyrus Poonawalla in 1966. The billionaire also owns private.. DNA - Published on November 17, 2023
Meet Yohan Poonawalla, Adar Poonawalla's cousin, collector with cars worth over Rs 100 crore, bigger than Mukesh Ambani Yohan Poonawalla is the Chairman of Poonawalla Engineering Group and El-O- Matic India Pvt Ltd and he is also a shareholder in Serum Institute of India Pvt Ltd and Chairman of Poonawalla Financials Pvt.. DNA - Published on September 29, 2023	Cyrus Poonawalla: The Son Of A Horse Breeder Who Didn't Follow His Family's Footsteps But Carved His Own Path And Now Has A Net Worth Of Rs 2,25,000 Crore Cyrus Poonawalla founded the Serum Institute of India (SII) in 1966, which is today the world's largest vaccine manufacturer. Zee News - Published on July 16, 2023
Age is just a number, look at Ratan Tata, Bachchan: NCP Lok Sabha member Supriya Sule takes on Ajit Pawar "Some people are saying that people who are senior now should give us their blessings (and retire). Why should they stop working? Ratan Tata who heads India's largest conglomerate is 86 years old... IndiaTimes - Published on July 5, 2023	This man leads India's most valuable unlisted company worth Rs 1.92 lakh crore, not Mukesh Ambani, Ratan Tata, Adani Adar Poonawalla's Serum Institute of India (SII), which became a household name for developing Covid-19 vaccines, is ranked as India's most valuable unlisted company, DNA - Published on June 21, 2023
Bombay HC says content posted against Covishield vaccine prima facie defamatory The Bombay High Court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and.. Mid-Day - Published on June 5, 2023	Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HC The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and.. IndiaTimes - Published on June 5, 2023Also reported by •Mid-Day
A New Beacon of Education - Utkal Gaurav International School Shines Bright in the Remote Village of Berunapadi, Odisha Several titans of business, academics, sports, medicine and arts have come together in an unknown village Berunapadi, of Odisha, to commemorate the opening of the Utkal Gaurav International School.. NewsVoir - Published on May 19, 2023	Serum Institute to double investment in Biocon's unit to $300 million IndiaTimes - Published on April 25, 2023
Covovax for adults to reach metros in a week: SII Serum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech.. IndiaTimes - Published on April 14, 2023	DNA Explainer: What is R21/Matrix-M, Oxford-Serum Institute's 'world-changer' malaria vaccine? The R21 vaccine, created at Oxford University and approved by the Ghanaian Food and Drugs Authority, is now available to the age group most at risk of malaria-related mortality. DNA - Published on April 14, 2023
SII to restart vaccine production amid surge in Covid cases Serum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus.. IndiaTimes - Published on April 12, 2023	Serum Institute of India restarts manufacturing of Covid-19 vaccine Covishield Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the.. IndiaTimes - Published on April 12, 2023
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults IndiaTimes - Published on April 3, 2023Also reported by •Zee News	ET GrandMasters, an OTT Platform for Business Learning from Top Corporate Leaders of the Country India's leading destination for consuming business & economy related news, Economic Times Digital has now launched a new OTT platform called *ET GrandMasters*. *ET GrandMasters, an OTT Platform from.. NewsVoir - Published on February 22, 2023
Serum Institute to set up CoE for Infectious Diseases and Pandemic Preparedness in Hyderabad newKerala.com - Published on February 19, 2023	Serum Institute of India launches first made-in-India HPV vaccine for cervical cancer newKerala.com - Published on January 24, 2023
DGCI approves market authorisation of Serum Institute's Covovax as booster dose newKerala.com - Published on January 17, 2023	Drug panel favours nod for Covovax as Covid booster An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have.. IndiaTimes - Published on January 12, 2023
Covovax may get approval as heterologous booster The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for.. IndiaTimes - Published on January 10, 2023	Covid situation in India better than elsewhere: SII CEO Adar Poonawalla Serum Institute CEO Adar Poonawalla on Sunday lauded India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic. "Everyone.. IndiaTimes - Published on January 9, 2023
Covid-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the.. IndiaTimes - Published on January 8, 2023